Nuclear EGFR as a molecular target in cancer von Brand, Toni M, Iida, Mari, Luthar, Neha, Starr, Megan M, Huppert, Evan J, Wheeler, Deric L

Volltext

AXL mediates resistance to cetuximab therapy von Brand, Toni M, Iida, Mari, Stein, Andrew P, Corrigan, Kelsey L, Braverman, Cara M, Luthar, Neha, Toulany, Mahmoud, Gill, Parkash S, Salgia, Ravi, Kimple, Randall J, Wheeler, Deric L

Volltext

Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer von Brand, Toni M, Iida, Mari, Dunn, Emily F, Luthar, Neha, Kostopoulos, Kellie T, Corrigan, Kelsey L, Wleklinski, Matthew J, Yang, David, Wisinski, Kari B, Salgia, Ravi, Wheeler, Deric L

Volltext

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab von Iida, Mari, Brand, Toni M, Starr, Megan M, Li, Chunrong, Huppert, Evan J, Luthar, Neha, Pedersen, Mikkel W, Horak, Ivan D, Kragh, Michael, Wheeler, Deric L

Volltext

Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3 von Brand, Toni M, Iida, Mari, Luthar, Neha, Wleklinski, Matthew J, Starr, Megan M, Wheeler, Deric L

Volltext

Corrigendum to: “Nuclear EGFR as a molecular target in cancer” [Radiother Oncol 108 (2013) 370–77] von Brand, Toni M., Iida, Mari, Luthar, Neha, Starr, Megan M., Huppert, Evan J, Wheeler, Deric L.

Volltext

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy von Iida, Mari, Brand, Toni M, Starr, Megan M, Huppert, Evan J, Luthar, Neha, Bahrar, Harsh, Coan, John P, Pearson, Hannah E, Salgia, Ravi, Wheeler, Deric L

Volltext

Correction: Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-negative Breast Cancer von Brand, Toni M, Iida, Mari, Dunn, Emily F, Luthar, Neha, Kostopoulos, Kellie T, Corrigan, Kelsey L, Wleklinski, Matthew J, Yang, David, Wisinski, Kari B, Salgia, Ravi, Wheeler, Deric L

Volltext

Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab von Iida, Mari, Brand, Toni M., Campbell, David A., Starr, Megan M., Luthar, Neha, Traynor, Anne M., Wheeler, Deric L.

Volltext

Abstract 5646: Overcoming acquired resistance to cetuximab by dual targeting of HER family members using antibody based therapy von Iida, Mari, Brand, Toni M., Starr, Megan M., Luthar, Neha, Wleklinski, Matthew J., Wheeler, Deric L.

Volltext

Abstract 4276: Mapping C-terminal transactivation domains of nuclear HER family receptor tyrosine kinases von Brand, Toni M., Iida, Mari, Wleklinski, Matthew J., Luthar, Neha, Starr, Megan M., Wheeler, Deric L.

Volltext

Abstract LB-219: Nuclear EGFR serves as a functional molecular target in triple-negative breast cancer von Brand, Toni M., Iida, Mari, Luthar, Neha, Wleklinski, Matthew, Kostopoulos, Kellie, Wheeler, Deric L.

Volltext

Abstract LB-215: The TAM family of receptor tyrosine kinases play a role in acquired resistance to cetuximab von Brand, Toni Michel, Iida, Mari, Corrigan, Kelsey L., Luthar, Neha, Hornung, Megan, Toulany, Mahmoud, Gill, Parkash, Salgia, Ravi, Wheeler, Deric L.

Volltext

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab1 von Iida, Mari, Brand, Toni M, Starr, Megan M, Li, Chunrong, Huppert, Evan J, Luthar, Neha, Pedersen, Mikkel W, Horak, Ivan D, Kragh, Michael, Wheeler, Deric L

Volltext

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3. e71518 von Brand, Toni M, Iida, Mari, Luthar, Neha, Wleklinski, Matthew J, Starr, Megan M, Wheeler, Deric L

Volltext